MX2023011796A - Métodos de tratamiento del cáncer con anticuerpos inmunorreceptor de células t con dominios ig e itim (anti-tigit). - Google Patents

Métodos de tratamiento del cáncer con anticuerpos inmunorreceptor de células t con dominios ig e itim (anti-tigit).

Info

Publication number
MX2023011796A
MX2023011796A MX2023011796A MX2023011796A MX2023011796A MX 2023011796 A MX2023011796 A MX 2023011796A MX 2023011796 A MX2023011796 A MX 2023011796A MX 2023011796 A MX2023011796 A MX 2023011796A MX 2023011796 A MX2023011796 A MX 2023011796A
Authority
MX
Mexico
Prior art keywords
methods
treating cancer
tigit antibodies
antibody
tigit
Prior art date
Application number
MX2023011796A
Other languages
English (en)
Inventor
Shyra Gardai
Alyson Smith
Original Assignee
Seagen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Seagen Inc filed Critical Seagen Inc
Publication of MX2023011796A publication Critical patent/MX2023011796A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

En el presente documento se proporcionan métodos para tratar el cáncer con un anticuerpo anti-TIGIT en combinación con un anticuerpo anti-PD-1 y/o un anticuerpo anti-PD-L1.
MX2023011796A 2021-04-09 2022-04-08 Métodos de tratamiento del cáncer con anticuerpos inmunorreceptor de células t con dominios ig e itim (anti-tigit). MX2023011796A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163173216P 2021-04-09 2021-04-09
PCT/US2022/023973 WO2022217026A1 (en) 2021-04-09 2022-04-08 Methods of treating cancer with anti-tigit antibodies

Publications (1)

Publication Number Publication Date
MX2023011796A true MX2023011796A (es) 2024-01-08

Family

ID=81448530

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023011796A MX2023011796A (es) 2021-04-09 2022-04-08 Métodos de tratamiento del cáncer con anticuerpos inmunorreceptor de células t con dominios ig e itim (anti-tigit).

Country Status (12)

Country Link
US (1) US20240025998A1 (es)
EP (1) EP4320160A1 (es)
JP (1) JP2024514816A (es)
KR (1) KR20230165911A (es)
CN (1) CN117730097A (es)
AU (1) AU2022254727A1 (es)
BR (1) BR112023020662A2 (es)
CA (1) CA3216170A1 (es)
IL (1) IL307556A (es)
MX (1) MX2023011796A (es)
TW (1) TW202304999A (es)
WO (1) WO2022217026A1 (es)

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
DE3883899T3 (de) 1987-03-18 1999-04-22 Sb2, Inc., Danville, Calif. Geänderte antikörper.
US5047335A (en) 1988-12-21 1991-09-10 The Regents Of The University Of Calif. Process for controlling intracellular glycosylation of proteins
WO1991000360A1 (en) 1989-06-29 1991-01-10 Medarex, Inc. Bispecific reagents for aids therapy
US5571894A (en) 1991-02-05 1996-11-05 Ciba-Geigy Corporation Recombinant antibodies specific for a growth factor receptor
US5278299A (en) 1991-03-18 1994-01-11 Scripps Clinic And Research Foundation Method and composition for synthesizing sialylated glycosyl compounds
WO1992020373A1 (en) 1991-05-14 1992-11-26 Repligen Corporation Heteroconjugate antibodies for treatment of hiv infection
US5587458A (en) 1991-10-07 1996-12-24 Aronex Pharmaceuticals, Inc. Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
AU3144193A (en) 1991-11-21 1993-06-15 Board Of Trustees Of The Leland Stanford Junior University Controlling degradation of glycoprotein oligosaccharides by extracellular glycosisases
DE69333807T2 (de) 1992-02-06 2006-02-02 Chiron Corp., Emeryville Marker für krebs und biosynthetisches bindeprotein dafür
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
US6245347B1 (en) 1995-07-28 2001-06-12 Zars, Inc. Methods and apparatus for improved administration of pharmaceutically active compounds
DE19541260A1 (de) 1995-11-06 1997-05-07 Lohmann Therapie Syst Lts Therapeutische Zubereitung zur transdermalen Applikation von Wirkstoffen durch die Haut
US5834597A (en) 1996-05-20 1998-11-10 Protein Design Labs, Inc. Mutated nonactivating IgG2 domains and anti CD3 antibodies incorporating the same
US6512010B1 (en) 1996-07-15 2003-01-28 Alza Corporation Formulations for the administration of fluoxetine
US6248864B1 (en) 1997-12-31 2001-06-19 Adherex Technologies, Inc. Compounds and methods and modulating tissue permeability
ES2340112T3 (es) 1998-04-20 2010-05-28 Glycart Biotechnology Ag Ingenieria de glicosilacion de anticuerpos para la mejora de la citotoxicidad celular dependiente de anticuerpos.
US6312717B1 (en) 1998-07-07 2001-11-06 Bristol-Myers Squibb Company Method for treatment of anxiety and depression
SE9802864D0 (sv) 1998-08-27 1998-08-27 Pharmacia & Upjohn Ab Transdermally administered tolterodine as antimuscarinic agent for the treatment of overactive bladder
JP2002536750A (ja) 1999-02-05 2002-10-29 サムスン エレクトロニクス カンパニー リミテッド 映像テキスチャー抽出方法及びその装置
US6544548B1 (en) 1999-09-13 2003-04-08 Keraplast Technologies, Ltd. Keratin-based powders and hydrogel for pharmaceutical applications
US6589549B2 (en) 2000-04-27 2003-07-08 Macromed, Incorporated Bioactive agent delivering system comprised of microparticles within a biodegradable to improve release profiles
JP4488740B2 (ja) 2001-11-13 2010-06-23 ダナ−ファーバー キャンサー インスティテュート，インコーポレイテッド 免疫細胞活性化を調節する作用剤およびその使用方法
CA2508660C (en) 2002-12-23 2013-08-20 Wyeth Antibodies against pd-1 and uses therefor
US7807165B2 (en) 2004-07-30 2010-10-05 Rinat Neuroscience Corp. Antibodies directed against amyloid-beta peptide and methods using same
NZ563193A (en) 2005-05-09 2010-05-28 Ono Pharmaceutical Co Human monoclonal antibodies to programmed death 1(PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics
SI1907424T1 (sl) 2005-07-01 2015-12-31 E. R. Squibb & Sons, L.L.C. Humana monoklonska protitelesa proti programiranem smrtnem ligandu 1 (PD-L1)
ES2523915T5 (es) 2006-12-01 2022-05-26 Seagen Inc Agentes de unión a la diana variantes y usos de los mismos
ES2437327T3 (es) 2007-06-18 2014-01-10 Merck Sharp & Dohme B.V. Anticuerpos para el receptor PD-1 humano de muerte programada
MX344415B (es) 2007-09-14 2016-12-15 Adimab Inc Bancos de anticuerpos sinteticos, designados racionalmente y usos para los mismos.
US8877688B2 (en) 2007-09-14 2014-11-04 Adimab, Llc Rationally designed, synthetic antibody libraries and uses therefor
EP2262837A4 (en) 2008-03-12 2011-04-06 Merck Sharp & Dohme PD-1 BINDING PROTEINS
CA2719189C (en) 2008-04-09 2020-08-04 Genentech, Inc. Novel compositions and methods for the treatment of immune related diseases
PL2282773T3 (pl) 2008-05-02 2014-08-29 Seattle Genetics Inc Sposoby i kompozycje do wytwarzania przeciwciał i pochodnych przeciwciał o obniżonej fukozylacji rdzeniowej
SI2342226T1 (sl) 2008-09-26 2016-11-30 Dana-Farber Cancer Institute Inc. Humana protitelesa proti PD-1, PD-L1 in PD-L2 in njihove uporabe
CN114835812A (zh) 2008-12-09 2022-08-02 霍夫曼-拉罗奇有限公司 抗-pd-l1抗体及它们用于增强t细胞功能的用途
EP2393835B1 (en) 2009-02-09 2017-04-05 Université d'Aix-Marseille Pd-1 antibodies and pd-l1 antibodies and uses thereof
JP2013512251A (ja) 2009-11-24 2013-04-11 アンプリミューン、インコーポレーテッド Ｐｄ−ｌ１／ｐｄ−ｌ２の同時阻害
WO2011082400A2 (en) 2010-01-04 2011-07-07 President And Fellows Of Harvard College Modulators of immunoinhibitory receptor pd-1, and methods of use thereof
CA2802344C (en) 2010-06-18 2023-06-13 The Brigham And Women's Hospital, Inc. Bi-specific antibodies against tim-3 and pd-1 for immunotherapy in chronic immune conditions
US8907053B2 (en) 2010-06-25 2014-12-09 Aurigene Discovery Technologies Limited Immunosuppression modulating compounds
KR102318383B1 (ko) 2010-07-16 2021-10-27 아디맵 엘엘씨 항체 라이브러리
KR20220042248A (ko) * 2013-07-16 2022-04-04 제넨테크, 인크. Pd-1 축 결합 길항제 및 tigit 억제제를 사용한 암을 치료하는 방법
TWI724997B (zh) 2014-08-19 2021-04-21 美商默沙東藥廠 抗ｔｉｇｉｔ抗體
MY187045A (en) 2014-12-23 2021-08-27 Bristol Myers Squibb Co Antibodies to tigit
TWI715587B (zh) 2015-05-28 2021-01-11 美商安可美德藥物股份有限公司 Ｔｉｇｉｔ結合劑和彼之用途
CN112638944A (zh) 2018-08-23 2021-04-09 西进公司 抗tigit抗体
WO2021258337A1 (en) * 2020-06-24 2021-12-30 Huahui Health Ltd. Human monoclonal antibodies against tigit for immune related diseases

Also Published As

Publication number Publication date
KR20230165911A (ko) 2023-12-05
US20240025998A1 (en) 2024-01-25
BR112023020662A2 (pt) 2024-02-06
JP2024514816A (ja) 2024-04-03
WO2022217026A1 (en) 2022-10-13
IL307556A (en) 2023-12-01
CA3216170A1 (en) 2022-10-13
TW202304999A (zh) 2023-02-01
CN117730097A (zh) 2024-03-19
AU2022254727A9 (en) 2023-10-26
EP4320160A1 (en) 2024-02-14
AU2022254727A1 (en) 2023-10-12

Similar Documents

Publication Publication Date Title
PH12020552221A1 (en) Anti-pd-1 antibodies and uses thereof
MX2020008882A (es) Dosificación para tratamiento con anticuerpos antagonistas anti-tigit y anti-pd-l1.
BR112018011029A2 (pt) métodos para tratar ou atrasar a progressão do câncer e para melhorar a função imune em um indivíduo com câncer, usos de um antagonista de ligação e de um anticorpo biespecífico, composições e kits
IL279251A (en) Methods for treating cancer with bispecific antibodies against CD3XMUC16 and antibodies against PD-1
MX2021010119A (es) Tratamiento combinado con anticuerpos anti-cd39 y anticuerpos anti-pd1 o anti-pd-l1.
MX2022003517A (es) Anticuerpos anti-pd l1 y conjugados de anticuerpo-farmaco.
MX2021012767A (es) Metodos para tratar el cancer de prostata con un anticuerpo anti-psma/cd3.
MX2021010116A (es) Anticuerpo anti-pd-l1 y uso de este.
MX2023004941A (es) Conjugado de anticuerpo y fármaco para terapia de combinación con inhibidor de células inmunitarias.
MX2020002301A (es) Terapia de combinacion de anticuerpos anti receptor del factor estimulante de colonias 1 (csf1r) y anti proteina de muerte programada 1 (pd-1) combinados para cancer pancreatico.
MX2021003673A (es) Anticuerpos anti-vsig4 humano y usos de los mismos.
MX2022005157A (es) Aprovechamiento de la energia de la microbiota y los metabolitos para el tratamiento del cancer.
MX2022008421A (es) Anticuerpo anti-galectina-9 y usos del mismo.
EP4104855A4 (en) USE OF AN ANTI-PD-1 ANTIBODY IN THE TREATMENT OF NEUROENDOCRINE TUMORS
MX2021012765A (es) Metodos para tratar el cancer renal con un anticuerpo anti-psma/cd3.
SA521422250B1 (ar) أجسام مضادة للبيريوستين واستخداماتها
MX2023011796A (es) Métodos de tratamiento del cáncer con anticuerpos inmunorreceptor de células t con dominios ig e itim (anti-tigit).
PH12020552159A1 (en) Poziotinib combinations with an anti-her1, her2 or her4 antibody and methods of use thereof
MX2021005686A (es) Combinacion farmaceutica de anti-ceacam6 y anticuerpos anti-pd-1 o anti-pd-l1 para el tratamiento del cancer.
ZA202213434B (en) Anti-lilrb1 antibody and uses thereof
MX2022006728A (es) Metodos y combinaciones para el tratamiento del cancer utilizando anticuerpos inhibidores de puntos de control inmunitario.
IL287687A (en) Methods of treating cancer with an anti-pd-l1 antibody
MX2023007780A (es) Terapia de combinacion usando un anticuerpo anti-fucosil-gm1.
MX2021001604A (es) Tratamiento del cáncer con un anticuerpo.
MX2022002363A (es) Sistema receptor de antígeno quimérico y usos de este.